DRUG ASSAYS

KRIBIOLISA™ Rituximab (RITUXAN®) ELISA
KRIBIOLISA™ Infliximab (REMICADE®) ELISA
KRIBIOLISA™ Alemtuzumab (LEMTRADA®) ELISA
KRIBIOLISA™ Etarnacept (ENBREL®) ELISA
KRIBIOLISA™ Ustekinumab (STELARA) ELISA
KRIBIOLISA™ Adalimumab (HUMIRA®)ELISA
KRIBIOLISA™ Bevacuzimab (AVASTIN®) ELISA
KRIBIOLISA™ Trastuzumab (HERCEPTIN) ELISA
KRIBIOLISA™ Humanized Anti-Her2/neu (Herceptin/Trastuzumab) ELISA
KRIBIOLISA™ Cetuximab (ERBITUX®) ELISA
KRIBIOLISA™ Golimumab (SIMPONI®) ELISA
KRIBIOLISA™ Natalizumab (TYSABRI®) ELISA
KRIBIOLISA™ Omalizumab (XOLAIR®) ELISA
KRIBIOLISA™ Tocilizuma b (ACTEMRA®) ELISA
KRIBIOLISA™ Eculizumab (SOLIRIS®) ELISA
KRIBIOLISA™ Ipilimumab (YERVOY®) ELISA
KRIBIOLISA™ Denosumab (PROLIA®) ELISA
KRIBIOLISA™ Atezolizumab (TECENTRIQ®) ELISA
KRIBIOLISA™ Daratumumab (DARZALEX®) ELISA
KRIBIOLISA™ Ranibizumab (LUCENTIS®) ELISA

ANTI-DRUG ANTIBODY ASSAYS

KRIBIOLISA™ Anti-Rituximab (RITUXAN®) ELISA
KRIBIOLISA™ Anti-Infliximab (REMICADE®) ELISA
KRIBIOLISA™ Anti-Alemtuzumab (LEMTRADA®) ELISA
KRIBIOLISA™ Anti-Etarnacept (ENBREL®) ELISA
KRIBIOLISA™ Anti-Ustekinumab (STELARA®) ELISA
KRIBIOLISA™ Anti-Adalimumab (HUMIRA®)ELISA
KRIBIOLISA™ Anti-Bevacuzimab (AVASTIN®) ELISA
KRIBIOLISA™ Anti-Trastuzumab (HERCEPTIN®) ELISA
KRIBIOLISA™ Anti-Cetuximab (ERBITUX®) ELISA
KRIBIOLISA™ Anti-Golimumab (SIMPONI®) ELISA
KRIBIOLISA™ Anti-Natalizumab (TYSABRI®) ELISA
KRIBIOLISA™ Anti-Omalizumab (XOLAIR®) ELISA
KRIBIOLISA™ Anti-Tociliz umab (ACTEMRA®) ELISA
KRIBIOLISA™ Anti Eculizumab (SOLIRIS®) ELISA
KRIBIOLISA™ Anti-Ipilimumab (YERVOY®) ELISA
KRIBIOLISA™ Anti-Denosumab (PROLIA®) ELISA
KRIBIOLISA™ Anti-Atezolizumab (TECENTRIQ®) ELISA
KRIBIOLISA™ Anti-Daratumumab (DARZALEX®) ELISA

elisa

CE
IVD

KRISHGEN BioSystems
OUR REAGENTS. YOUR RESEARCH.

www.stratech.co.uk/krishgen info@stratech.co.uk

KRISHGEN BioSystems

OUR REAGENTS. YOUR RESEARCH.

THE FOREFRONT OF BIOLOGICS MONITORING

CE
Marked Kits

ADALIMUMAB

Stratech

KRIBIOLISA™ ASSAY KITS

KRIBIOLISA ADALIMUMAB ELISA

KRIBIOLISA ANTI-ADALIMUMAB ELISA

www.stratech.co.uk/krishgen

OUR PHILOSOPHY IS TO DELIVER THE BEST ASSAY AND TOOLS FOR YOUR SCIENCE.

ASSAY KIT PARTICULARS :

KRIBIOLISA™ ADALIMUMAB ELISA
KIT CATALOG NUMBER: KBI1015
TYPE OF ASSAY: ELISA, SANDWICH BASED
SAMPLE MATRIX: SERUM, PLASMA, CELL CULTURE SUPERNATANT
CALIBRATOR RANGE: 0 -100 NG/ML

REGULATORY STATUS:
IN USA : FOR RESEARCH USE
IN EUROPE : CE MARKED, FOR IVD USE

KRIBIOLISA™ ANTI-ADALIMUMAB ELISA
KIT CATALOG NUMBER: KBI2015
TYPE OF ASSAY: ELISA, SANDWICH BASED
SAMPLE MATRIX: SERUM, PLASMA, CELL CULTURE SUPERNATANT
CALIBRATOR RANGE: 0 - 100 NG/ML

REGULATORY STATUS:
IN USA : FOR RESEARCH USE
IN EUROPE : CE MARKED, FOR IVD USE

VALIDATION:
AS PER ICH AND FDA GUIDELINES FOR BIOLOGICAL ASSAYS

ADALIMUMAB - TNF BLOCKER DRUG

Drug Class: Monoclonal Antibodies; DMARDs, TNF Inhibitors; Antipsoriatics, Systemic; Inflammatory Bowel Disease Agents

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, juvenile idiopathic, ankylosing spondylitis, psoriatic).

Adalimumab is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa).It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis.

Adalimumab belongs to a class of drugs known as TNF blockers.

By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function.

Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

OUR KRIBIOLISA™ ADALIMUMAB ELISA HAS A SENSITIVE RANGE : 0 - 100 NG/ML FOR SERUM MEASUREMENTS.

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis - A Step Toward Personalized Treatment

Stef P. Menting, MD1; Emma Coussens, MD2; Mieke F. Pouw, MSc3,4; et al Juul M. P. A. van den Reek, MD5; Linda Temmerman, MD6; Hugo Boonen, MD7; Elke M. G. J. de Jong, MD, PhD5; Phyllis I. Spuls, MD, PhD1; Jo Lambert, MD, PhD2
Author Affiliations Article Information: JAMA Dermatol. 2015;151(6):616-622. doi:10.1001/jamadermatol.2014.5479

Abstract
Importance Adalimumab has proven to be effective in suppressing psoriasis disease activity and is administered in a standard dose.
Objective To establish a therapeutic range for adalimumab trough levels in the treatment of plaque-type psoriasis, leading to a more personalized treatment.

Main Outcomes and Measures Adalimumab trough level and PASI score at the time of serum sampling to determine the receiver-operator characteristics analyses and concentration effect curve.

Results By means of receiver-operator characteristics analyses with an area under the curve of 0.756 (SD, 0.046; 95% CI, 0.666-0.847) and a sensitivity of 78% and a specificity of 70%, 3.51 mg/L was established as the lower margin for the therapeutic range. By means of a concentration effect curve, 7 mg/L was established as the upper margin. One-third of patients had an adalimumab trough concentration exceeding 7 mg/L.

Conclusions and Relevance A therapeutic range of adalimumab trough levels of 3.51 mg/L to 7.00 mg/L, which corresponds to an optimal clinical effect, was identified. In one-third of patients, it was observed that trough concentrations exceeded the therapeutic window. Based on the established range, a therapeutic algorithm for adalimumab treatment for patients with psoriasis can be developed and validated in a prospective patient cohort. Developing a therapeutic algorithm may lead to less overtreatment of patients and cost savings.

KRISHGEN BioSystems
OUR REAGENTS. YOUR RESEARCH.

KRIBIOLISA™ ADALIMUMAB ELISA
KRIBIOLISA™ ANTI-ADALIMUMAB ELISA

High Sensitivity Assays:
Limit of Detection: 1.56 NG/ML

Seven Point Calibration Curve for High Degree Of Accuracy

PRINCIPAL OF THE ASSAY + KIT PARAMETERS

KRIBIOLISA™ ADALIMUMAB ELISA
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Adalimumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Adalimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Adalimumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Adalimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

KRIBIOLISA™ ANTI-ADALIMUMAB ELISA
The method employs the quantitative sandwich enzyme immunoassay technique. Adalimumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Adalimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Adalimumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Adalimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

CALIBRATORS VALIDATION + KIT PARAMETERS

KRIBIOLISA™ ADALIMUMAB ELISA
The Calibrators have been standardized against innovator drug- Humira® sourced commercially.

KRIBIOLISA™ ANTI-ADALIMUMAB ELISA
The Calibrators have been standardized against antibodies to Adalimumab sourced commercially.

PERFORMANCE CHARACTERISTICS + KIT PARAMETERS

KRIBIOLISA™ ADALIMUMAB ELISA
Sensitivity (LOD) : 1.56 NG/ML Precision: Inter/Intra Assay: < 10% Cross Reactivity: Adalimumab, 100%

KRIBIOLISA™ ANTI-ADALIMUMAB ELISA
Sensitivity (LOD) : 1.56 NG/ML Precision: Inter/Intra Assay: < 10% Cross Reactivity: Adalimumab, 100%